Recent Updates
Recently added Catalysts
RMD Positive Sentiment Score: 70/100

For media For investors news@resmed.com investorrelations@resmed.com +1 858.836.6798 +1 858.836.5000 ResMed Chief Administrative Officer and Global General Counsel to Retire ResMed to conduct an internal search for a suc

Key Takeaway: ResMed announced the retirement of David Pendarvis, Chief Administrative Officer and Global General Counsel, effective June 30, 2023. He will assist in a consulting role until December 31, 2023. The company plans to find a successor for Pendarvis’s roles through an internal search prior to his retirement. Amy Wakeham is appointed as the new Chief Communications and Investor Relations Officer, reflecting ResMed's focus on leadership continuity.

Market Sentiment Analysis

POSITIVE FACTORS

  • David Pendarvis has served ResMed for over 20 years, contributing greatly to its transformation.
  • The company is conducting an internal search, indicating a strong leadership pipeline.
  • Amy Wakeham has been appointed to a key position, reflecting ResMed's commitment to promoting internal talent.

Full Press Release Details

For media For investors
news@resmed.com investorrelations@resmed.com
+1 858.836.6798 +1 858.836.5000
ResMed Chief Administrative Officer and Global General Counsel to Retire
SAN DIEGO, March 30, 2023 ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief
administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023.
ResMed will conduct an internal search for the successor to Pendarvis legal roles and expects to name a new global general counsel and secretary well
ahead of David s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor
Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will join ResMed s executive leadership team, effective April 1, 2023.
Dave has been an integral part of ResMed for over 20 years, helping guide the company into and through its transformation from the pioneer of sleep
apnea treatment to a $30 billion-plus global leader in digital health and cloud-connected medical devices, said CEO Mick Farrell. On behalf of the entire management team and the board, I want to thank Dave for his two decades of
dedicated service and exemplary leadership that has helped build the industry-leading company that ResMed is today. He s been an important leader in an executive team that has positioned ResMed to improve the lives of many millions of people
living with chronic respiratory diseases and countless more seeking to age healthily and outside the hospital. Personally, Dave has been a trusted advisor, partner, friend, and mentor to me through the years, I will miss his guidance, insights, and
quick sense of humor.
My best wishes to Dave on a much-deserved retirement, and congratulations to Amy on her well-earned appointment,
Farrell said. Through an internal search process, we will identify a well-qualified successor for the global general counsel role ahead of Dave s retirement to ensure a smooth transition into these critical roles. This speaks to the
overall depth of ResMed s leadership bench strength and broad expertise across our global team of over 10,000 ResMedians as we continue to execute our strategy that will help 250 million people sleep, breathe, and live healthier lives in
Pendarvis, age 64, retires after a nearly 40-year career in law and
business. He joined ResMed in 2002, following private practice as a partner with the firms of Gibson Dunn and Gray Cary Ware & Freidenrich (now DLA Piper). He has had several roles at ResMed: global general counsel, secretary, senior vice
president of organizational development, chief administrative officer, and interim president Europe, Middle East, Africa, and Japan.
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live
healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life,
reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Frequently Asked Questions

Who is retiring from ResMed?

David Pendarvis, ResMed's Chief Administrative Officer and Global General Counsel, is retiring.

When is David Pendarvis's retirement effective?

His retirement is effective June 30, 2023.

Who will succeed Pendarvis in his roles?

Amy Wakeham will succeed him as Chief Communications and Investor Relations Officer.

How long has Pendarvis been with ResMed?

David Pendarvis has been with ResMed for over 20 years.

What role will Pendarvis hold after retirement?

He will remain as a consultant with ResMed until December 31, 2023.

Last updated: Mar 30, 2023